Amedisys (Nasdaq: AMED) exceeded Wall Street expectations in its first-quarter results for 2025. The company’s home health segment benefited from ...

Amedisys (AMED) delivered earnings and revenue surprises of 10.62% and 0%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Although home-based care providers and industry experts initially entered 2025 with a renewed level of optimism regarding ...

Amedisys delivers first-quarter top-line growth across three of its segments, namely Home Health, Hospice and High Acuity Care. Although the revenue and EPS for Amedisys (AMED) give a sense of how ...

Amedisys, Inc. (the “Company”) is a leading healthcare services company, delivering personalized home health, hospice and high acuity care services in the home. Amedisys is focused on ...

Amedisys spurned a previous $3.6 billion all-stock bid from infusion company Option Care Health UnitedHealth Group operates home health and hospice locations in 37 states under its LHC Group ...

Amedisys (AMED) came out with quarterly earnings ... A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.05 per share when it actually ...

Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March ...

Amedisys, Inc. (the "Company”) is a leading healthcare services company, delivering personalized home health, hospice and high acuity care services in the home. Amedisys is focused on delivering the ...

Advertisement Article continues below this ad The home health care and hospice services provider posted revenue of $594.8 million in the period, which met Street forecasts. Amedisys shares have ...